Autologous skeletal myoblast patch implantation prevents the deterioration of myocardial ischemia and right heart dysfunction in a pressure-overloaded right heart porcine model

Kanta Araki, Shigeru Miyagawa, Takuji Kawamura, Ryo Ishii, Tadashi Watabe, Akina Harada, Masaki Taira, Koichi Toda, Toru Kuratani, Takayoshi Ueno, Yoshiki Sawa*

1 Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine, Osaka, Japan, 2 Department of Pediatrics, Osaka University Graduate School of Medicine, Osaka, Japan, 3 Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, Osaka, Japan

* sawa-p@surg1.med.osaka-u.ac.jp

Abstract

Right ventricular dysfunction is a predictor for worse outcomes in patients with congenital heart disease. Myocardial ischemia is primarily associated with right ventricular dysfunction in patients with congenital heart disease and may be a therapeutic target for right ventricular dysfunction. Previously, autologous skeletal myoblast patch therapy showed an angiogenic effect for left ventricular dysfunction through cytokine paracrine effects; however, its efficacy in right ventricular dysfunction has not been evaluated. Thus, this study aimed to evaluate the angiogenic effect of autologous skeletal myoblast patch therapy and amelioration of metabolic and functional dysfunction, in a pressure-overloaded right heart porcine model. Pulmonary artery stenosis was induced by a vascular occluder in minipigs; after two months, autologous skeletal myoblast patch implantation on the right ventricular free wall was performed (n = 6). The control minipigs underwent a sham operation (n = 6). The autologous skeletal myoblast patch therapy alleviated right ventricular dilatation and ameliorated right ventricular systolic and diastolic dysfunction. 11C-acetate kinetic analysis using positron emission tomography showed improvement in myocardial oxidative metabolism and myocardial flow reserve after cell patch implantation. On histopathology, a higher capillary density and vascular maturity with reduction of myocardial ischemia were observed after patch implantation. Furthermore, analysis of mRNA expression revealed that the angiogenic markers were upregulated, and ischemic markers were downregulated after patch implantation. Thus, autologous skeletal myoblast patch therapy ameliorated metabolic and functional dysfunction in a pressure-overloaded right heart porcine model, by alleviating myocardial ischemia through angiogenesis.
Introduction

The prognosis of patients with congenital heart disease (CHD) is improving with advances in treatment strategies and interventions [1–3]. However, long-term cardiac overload owing to anatomical features and residual lesions after repair leads to heart failure [4–6], especially right heart failure [7,8], which is also known to be a predictor for poor outcomes [4,8–11]. Myocardial ischemia is primarily associated with right ventricular dysfunction, causing right heart failure in patients with CHD [4,8,12–20]. Thus, myocardial ischemia could be a potential therapeutic target for right heart failure. Specific treatments for right heart failure in patients with CHD are not well elucidated [8,21–24], and even ventricular assist device therapy and heart transplantation remain challenging treatments in patients with CHD and are not suitable for all of them [25–29].

In recent years, regenerative treatments such as cell therapy have gained increasing attention as newer treatment options for left heart failure and are progressively being integrated into clinical use [30,31]. Previously, we revealed the clinical efficacy of autologous skeletal myoblast patch transplantation therapy for left ventricular dysfunction associated with ischemic cardiomyopathy and dilated cardiomyopathy, through angiogenesis and anti-fibrosis, induced by cytokine paracrine effects in preclinical [32–37] and clinical studies [38–41]. These findings propose a possible efficacy of the same treatment for right ventricular dysfunction based on the ischemic etiology; however, this has not been evaluated before.

Hence, we hypothesized that autologous skeletal myoblast patch transplantation alleviated right ventricular dysfunction, and conducted a preclinical study using a pressure-overloaded right heart porcine model.

Material and methods

All studies were performed after the approval of the ethics review committee for animal experimentation of Osaka University Graduate School of Medicine, Osaka, Japan (reference number: 30-056-005). All animal care procedures were conducted in compliance with the Principles of Laboratory Animal Care formulated by the National Society for Medical Research and the Guide for the Care and Use of Laboratory Animals prepared by the Institute of Animal Resources and published by the National Institutes of Health (publication no: 85–23, revised 1996).

Preparation of animal models

Twelve Göttingen minipigs aged 5–6 months and weighing 10–12 kg (Oriental Yeast Corporation, Tokyo, Japan) were used in the experiments. The minipigs were anesthetized with an intravenous administration of ketamine (6 mg/kg) and sodium pentobarbital (10 mg/kg) for endotracheal intubation, and were maintained with inhaled isoflurane (1.5%–2%). The left intercostal space was opened to mount a vascular occluder (OA218-025; Unique Medical Co., Ltd., Tokyo, Japan) (Fig 1A) to the pulmonary artery trunk (Fig 1B). The pericardium was opened, and the vascular occluder was mounted to the pulmonary artery trunk and was connected to an access port (CP2AC-7Fr; Primetech Co., Ltd., Tokyo, Japan), which was implanted subcutaneously in the back. Pulmonary artery stenosis was gradually strengthened over a month to a stenosis velocity of over 3.0 m/s, evaluated using echocardiography by injecting 50% glycerin from the access port to inflate the vascular occluder. Pulmonary artery banding (PAB) was maintained at the same level of stenosis for the rest of the study period (Fig 1G). All the minipigs survived the induction of pulmonary artery stenosis, and two months after PAB, the degree of right ventricular dysfunction was checked using echocardiography and...
Fig 1. Preparation of animal models and skeletal myoblast patch. All minipigs underwent a PAB procedure by mounting the VO (a) to the pulmonary artery trunk (b) via the left intercostal space, harvesting the skeletal muscle from the quadriiceps femoris muscle (c) at the same time. The purified skeletal myoblast cells were isolated and cultured (d). Cell patches were fabricated using a temperature-responsive dish (e) and were placed on the epicardium of the right ventricular free wall (f). The protocol of the study is given in (g). PAB, pulmonary artery banding; VO,
cardiac computed tomography, for confirming the establishment of a pressure-overloaded right heart failure model.

**Cell patch transplantation**

Skeletal muscles weighing approximately 5 g were collected from the quadriceps femoris muscle during the PAB procedure (Fig 1C). Purified skeletal myoblast cells were cultured for three weeks as reported previously (Fig 1D) \[35\]. For quality control, the cell patch process was initiated after confirming that the cultured cells had a CD56 positivity rate of \( \geq 80\% \) using flow cytometry (BD FACSCanto2, BD Biosciences, New Jersey, USA). Cells were incubated in 100-mm temperature-responsive culture dishes (UpCell, CellSeed Inc., Tokyo, Japan) at 37˚C for 6 h. The number of incubated cells was \( 5 \times 10^6 \) per body weight of the minipigs, during transplantation. The dishes were then transferred to a clean bench at room temperature to release the cultured cells as intact cell patches. Using this protocol, skeletal myoblast cells spontaneously detached from the plates as free-floating monolayer cell patches (Fig 1E). Two months after the PAB procedure, minipigs were again placed under general anesthesia for either cell patch implantation (PATCH group, \( n = 6 \)), or a sham operation with opening of the pericardium through the right intercostal space (control group, \( n = 6 \)). The cell patch was placed on the epicardium of the right ventricular free wall (Fig 1F). Additionally, some fibrin glue was applied over the cell patches after their placement to attach them to the epicardium of the heart.

**Echocardiography**

Before the PAB procedure, and at two months after PAB (that is, before the patch implantation or sham operation), and furthermore, at four months after PAB (that is, two months after the patch implantation or sham operation), transthoracic echocardiography (TTE) was performed to measure right ventricular systolic and diastolic function using Vivid I (General Electric Healthcare, Chicago, USA) with a 6Tc-RS probe (General Electric Healthcare, Chicago, USA) under general anesthesia. The following parameters were evaluated using four chamber view images and tissue Doppler images: (1) Tei index of right ventricle, (2) right ventricular fraction area change (RVFAC), (3) tricuspid annular plane systolic excursion (TAPSE), (4) the ratio between early tricuspid inflow velocity and early tricuspid annular diastolic velocity (E/e’), (5) isovolumic contraction time (ICT), (6) isovolumic relaxation time (IRT), and (7) right ventricular free wall thickness (RVFWT).

**Electrocardiography-gated multidetector-row computed tomography**

Before the PAB procedure, and at two and four months after the PAB, electrocardiography-gated multidetector-row computed tomography (MDCT) was performed to measure the volume and contraction of the right ventricle. The images were taken in the supine position with a 16-slice multislice CT scanner (Somatron Emotion 16; Siemens Aktiengesellschaft, Munich, Germany) during end-expiratory breath hold, under general anesthesia. MDCT was performed after intravenous injection of a nonionic contrast medium (3 mL per bodyweight of the mini-pigs; Iomeprol; Bracco-Eisai Co Ltd, Tokyo, Japan). The axial images were reconstructed using the scanner software (Siemens Aktiengesellschaft, Munich, Germany). All
images were analyzed at a workstation (AZE; Virtual PI 64, AZE Co., Ltd., Tokyo, Japan). Right ventricular end-diastolic volume (RVEDV) and right ventricular end-systolic volume (RVESV) were obtained from the workstation, and RV ejection fraction (RVEF) was calculated using the following equation: $\text{RVEF} (%) = 100 \times (\text{RVEDV}/\text{RVESV})/\text{RVEDV}$.

**Pressure-volume loop analysis using cardiac catheterization**

Four months after the PAB (that is, two months after the patch implantation or sham operation), an invasive pressure-volume loop analysis was performed under general anesthesia. A tourniquet was placed under the inferior vena cava to change the ventricular preload. Arterial access was obtained by introducing a 6Fr sheath into the left carotid artery, and venous access was obtained by introducing a 7Fr sheath into the right carotid vein. 4Fr conductance and pressure-tip catheters (CA-41063-PN, CD Leycom, Zoetermeer, Netherlands) were inserted into the left and right ventricles through the sheaths in the carotid artery and carotid vein, under fluoroscopic guidance. The position of the catheter was determined by observing the pressure and segmental volume signals with appropriate phase relationships. The conductance and pressure transducer controllers (Conduct NT Sigma 5DF plus analysis system; CFL-M, CD Leycom, Zoetermeer, Netherlands) were set, and pressure-volume loops and intracardiac electrocardiograms were monitored online. The conductance, pressure, and intracardiac electrocardiographic signals were analyzed with Inca software (CD Leycom, Zoetermeer, Netherlands).

Under stable hemodynamic conditions, the baseline indices were initially measured, and the pressure-volume loop was then drawn during the inferior vena cava occlusion and analyzed. The following indices were calculated as the baseline left ventricular and right ventricular functions: heart rate (HR), ejection fraction (EF), end-systolic pressure (ESP), end-diastolic pressure (EDP), the maximum rate of the right ventricular pressure rise (dP/dt max), the maximal rate of fall of the right ventricular pressure (dP/dt min), and the time constant of isovolumic relaxation (Tau). The following relationships were determined by means of pressure-volume loop analysis, as load-independent measures of right ventricular function: end-systolic pressure-volume relationship (ESPVR) and end-diastolic pressure-volume relationship (EDPVR).

**11C-acetate positron emission tomography**

Two months after PAB (that is, before the patch implantation or sham operation), and four months after PAB (that is, two months after the patch implantation or sham operation), *in vivo* measurements of myocardial oxygen consumption (MVO$_2$) and myocardial blood flow (MBF) were performed using positron emission tomography (PET) scanning (Eminence-B SET-3000B/L; Shimadzu, Kyoto, Japan), on four minipigs in each group. The minipigs were sedated using a propofol infusion (1 mL/h), and with 1% isoflurane inhalation, and were positioned in a whole-body PET scanner at the Medical Imaging Center for Translational Research of Osaka University Graduate School of Medicine. A 5-min transmission scan was performed for correcting the emission images for photon attenuation. Immediately after the transmission scan, approximately 100 MBq of $^{11}$C-acetate was administered intravenously, and dynamic PET acquisition was initiated (15 mins). The measurements were performed under both resting conditions and high cardiac work state induced by catecholamine (dobutamine, 20 μg/kg per minute), as reported previously [42]. PET images were acquired in 30 frames (10 s × 6, 20 s × 6, 30 s × 12, and 60 s × 6) and were reconstructed with a dynamic row-action likelihood algorithm with an image matrix of 128 × 128. The PET images were analyzed using the software PMOD (Ver. 4.003, PMOD Japan Inc., Tokyo, Japan), where the right ventricle was also analyzed by flipping the PET image horizontally.

To determine the global cardiac oxygen consumption, the acetate clearance rates (myocardial oxidative consumption $[k_{\text{mono}}]$, of all segments of each measurement were averaged. The MBF was
calculated using the one-tissue compartment model. Both the values of $k_{mono}$ and MBF were derived from the subtraction of the preoperative test value from the postoperative test value, to represent the amount of change by treatment. RV efficiency was derived by combining cardiac catheterization data, CT data, and RV weight using the following equation as reported previously [43]: RV efficiency = $HR \times RVESP \times RVSV \times 1.33 \times 10^{-4} \times RVk_{mono} \times RV mass \times 20$, where RVSV is the RV stroke volume determined using CT, RVESP is the RV end-systolic pressure determined using cardiac catheterization, HR is heart rate determined using cardiac catheterization, RV $k_{mono}$ is the resting condition right ventricular $k_{mono}$ at two months after patch implantation or sham operation, and RV mass is the RV weight of the harvested heart.

### Histologic analyses

Four months after PAB (that is, two months after patch implantation or sham operation), the heart and liver were excised to perform histological and molecular biological analyses under general anesthesia. The hearts were removed, and the ventricles were dissected free of atrial tissue and large blood vessels. The RV was carefully separated from the left ventricle (LV) and the intraventricular septum. Fresh ventricular tissue was immediately blotted dry and weighed separately for determining the degree of RV hypertrophy based on two parameters: RV wall weight/biventricular weight (RV/BV), and RV wall weight/body weight (RV/BW). Fresh liver tissues were also immediately blotted dry and weighed for determining the degree of abdominal organ congestion owing to right heart failure: Liver weight/BW (Liver/BW).

The excised RV wall was fixed with either 10% buffered formalin for paraffin sections, or 4% paraformaldehyde for frozen sections. The paraffin sections of the RV were stained with picrosirius red for assessing the degree of myocardial fibrosis and were stained with Periodic Acid-Schiff for assessing myocardial cell size. The paraffin sections of the RV were used for immunohistochemistry, and were labeled using polyclonal CD31 antibody (1:50, Abcam, Cambridge, UK) and anti-$\alpha$-smooth muscle actin antibody (1:50, DAKO, Hovedstaden, Denmark) for assessing capillary vascular density and vascular maturity. Frozen sections of the RV were also used for immunohistochemistry and were labeled with dihydroethidium for estimating superoxide production. The paraffin sections of the liver were stained with hematoxylin-eosin for assessing the degree of congestion around the central vein in the hepatic lobule.

Data were analyzed and averaged from three randomly selected fields in the RV free wall and the RV anterior and posterior hinge points in each group. The fibrotic area was calculated as the percentage of the myocardial area using Metamorph image analysis software (Molecular Devices, Inc., Downingtown, PA, USA). BZ-analysis software (Keyence, Tokyo, Japan) was used for measuring the capillary density and dihydroethidium positive dots. Myocardial cell size was determined by drawing point-to-point perpendicular lines across the cross-sectional area of the cell at the level of the nucleus. The results were expressed as the average diameter of 10 myocytes randomly selected from each selected field by Periodic Acid-Schiff staining using a fluorescence microscope (BZ-9000, Keyence, USA).

### Real-time polymerase chain reaction

The RV free wall region of the excised heart samples was later immersed in an RNA stabilization solution (RNAlater, Invitrogen, Carlsbad, CA, USA). The total RNA was isolated from the infarct-border area using the RNeasy Kit (Qiagen, Hilden, Germany), and was reverse-transcribed using the Omniscript reverse transcriptase (Qiagen) enzyme. Real-time PCR was performed using TaqMan Gene Expression Assay Master Mix (Applied Biosystems, Foster City, CA, USA) on a 7500 Fast Real-Time PCR System (Applied Biosystems). The following genes were analyzed using the TaqMan Gene Expression Assay (Applied Biosystems): vascular
endothelial growth factor A, hepatocyte growth factor, C-X-C motif chemokine ligand 12, NADPH oxidase heavy chain subunit, NADPH oxidase 4, natriuretic peptide A, natriuretic peptide B, transforming growth factor beta 1, and cellular communication network factor 2. Glyceraldehyde-3-phosphate dehydrogenase was co-amplified as an internal control for RNA integrity.

Statistical analyses
All data were analyzed using the JMP Pro15 software (SAS Institute, Cary, NC, USA). All values were expressed as means ± standard deviation (SD). Comparisons between the two groups were performed using the Mann-Whitney U test. The differences were considered statistically significant at a P-value of <0.05.

Results
Amelioration of pressure-overloaded right ventricular dysfunction after patch implantation
The functional effect of autologous skeletal myoblast patches on the pressure-overloaded right ventricles was assessed using MDCT (Fig 2A) and TTE. The deterioration in RV volume, RVEF, and RV systolic and diastolic functions, at two months after PAB (before patch implantation) was not significantly different between the PATCH and the control groups (Fig 2B and 2C).

Two months after the patch implantation or sham operation, RV volume dilatation and reduction in RVEF were significantly alleviated in the PATCH group than in the control group (RVEDV: 47.5 ± 6.9 mL vs. 65.7 ± 7.4 mL, p = 0.01; RVESV: 27.8 ± 3.8 mL vs. 46.1 ± 5.2 mL, p < 0.01; RVEF: 41.3 ± 1.1% vs. 29.7 ± 4.0%, p < 0.01, PATCH vs. control, respectively) (Fig 2A).

In the TTE at two months after patch implantation or sham operation, the RV free wall thickness was not different in the groups (S1 Fig), but the RV systolic and diastolic functions were more significantly ameliorated in the PATCH group than in the control group (Tei index: 0.42 ± 0.08 vs. 0.68 ± 0.07, p < 0.01; RVFAC: 47.8 ± 2.2% vs. 19.2 ± 5.2%, p < 0.01; ICT: 46.0 ± 6.7 ms vs. 90.1 ± 9.8 ms, p < 0.01; TAPSE: 9.0 ± 1.2 mm vs. 5.1 ± 0.9 mm, p < 0.01; E/e’: 6.57 ± 1.24 vs. 10.11 ± 1.38, p < 0.01; IRT: 53.3 ± 7.8 ms vs. 99.7 ± 9.0 ms, p < 0.01, PATCH vs. control, respectively) (Figs 2B and S1).

Pressure-volume loop analysis at two months after patch implantation and sham operation also revealed a more significant alleviation of the RV systolic and diastolic functions in the PATCH group than in the control group (Table 1 and S2 Fig). However, there was no difference in the systemic RV pressure, and the ratio between the systemic RV pressure and systemic LV pressure (Table 1), which indicates that the level of pressure load on the RV was equal between the groups.

Significant improvement in myocardial oxidative metabolism in the patch implantation group
Based on the $^{11}$C-acetate PET conducted at 2 months after PAB (that is, before patch implantation or sham operation), and at 4 months after PAB (2 months after patch implantation or sham operation); the MVO$_2$ and MBF were measured at each point, and the preoperative values were subtracted from the postoperative values to evaluate the changes in the value between treatments (Fig 3).

The postoperative value of the $^{11}$C-acetate clearance rate constant $k$ ($k_{mono}$), which is an index of tricarboxylic acid (TCA) cycle activity, was lower than the preoperative value at rest conditions, and showed no difference between the groups (Table 2). However, under stress conditions with dobutamine administration, the change in $k_{mono}$ was positive in the PATCH group but was negative in the control group (Table 2). The ratio between the $k_{mono}$ at stress and rest conditions,
Fig 2. Changes in the right ventricular volume and right ventricular systolic and diastolic functions during the study. (a) Representative cardiac images of the four-chamber view and short axial view at the end-diastolic phase and end-systolic phase for each point. The RV volume was enlarged at the pre-treatment point compared to the baseline in either group, but at the post-treatment point, the enlargement of the RV volume was alleviated more in the PATCH group than in the control group. (b) Changes in the RV volume and RVEF at pre-treatment and post-treatment from
which is an index of the MVO$_2$ reserve, was positive in the PATCH group but was negative in the control group with a significant difference, which indicates a high activity reserve of the TCA cycle in the PATCH group (Table 2). RV efficiency calculated from RV work and RV oxygen consumption was significantly higher in the PATCH group than in the control group (Table 2).

Like the MVO$_2$, the postoperative value of the MBF was lower than the preoperative value at rest conditions and showed no difference between the groups (Table 2). However, under stress conditions with dobutamine administration, the change in MBF was positive in the PATCH group but was negative in the control group, with a significant difference (Table 2). The ratio between the MBFs at stress and rest conditions, which is an index of myocardial flow reserve, was positive in the PATCH group, but was negative in the control group with a significant difference, which indicates an increment of myocardial flow reserve after treatment in the PATCH group, but a decrease in the control group (Table 2).

### Myoblast cell patch attenuates pathological remodeling and myocardial ischemia in the pressure-overloaded right ventricular myocardium

The macropathological findings of the resected heart revealed a hypertrophied RV wall in both groups, however, the enlargement of the RV cavity was lesser in the PATCH group than in the baseline. The RV volume dilatation and reduction of RVEF were more significantly alleviated in the PATCH group than in the control group at the post-treatment point. (c) Changes in the systolic and diastolic functions of the RV at pre-treatment and post-treatment, from the baseline. The RV systolic and diastolic functions significantly ameliorated in the PATCH group than in the control group at the post-treatment point. The red and blue numbers at each point represent the mean ± standard deviation of the PATCH group and the control group, respectively. P-values were calculated using the Mann-Whitney U test. $P<0.05$, $P<0.01$ versus control group. RVEDV, right ventricular end-diastolic volume; RVESV, right ventricular end-systolic volume; RVEF, right ventricular ejection fraction; FAC, fraction area change; E/e', the ratio of early trans-tricuspid flow velocity to early diastolic velocity of the tricuspid annulus.

https://doi.org/10.1371/journal.pone.0247381.g002

| Table 1. Analysis of hemodynamic indices at two months after patch implantation. |
|---------------------------------|-----------------|-----------------|------------------|
|                                | Control (n = 6) | PATCH (n = 6)   | P-value          |
| Basic hemodynamic indices      |                 |                 |                  |
| HR (bpm)                        | 75 ± 14         | 124 ± 26        | 0.013            |
| RVEF (%)                        | 23.7 ± 11.1     | 44.6 ± 9.6      | 0.008            |
| RVESP (mmHg)                    | 28.6 ± 10.2     | 35.9 ± 7.8      | 0.128            |
| RVESP/LVESP (mmHg)              | 0.57 ± 0.17     | 0.75 ± 0.16     | 0.230            |
| RVEDP (mmHg)                    | 7.5 ± 1.3       | 2.9 ± 2.2       | 0.006            |
| dP/dt max (mmHg/sec)            | 179 ± 55        | 425 ± 135       | 0.008            |
| dP/dt min (mmHg/sec)            | −205 ± 76       | −391 ± 112      | 0.013            |
| Tau (ms)                        | 51.8 ± 11.4     | 32.2 ± 6.7      | 0.005            |
| Load-independent parameters analyzed using PV loop | | | |
| ESPVR (mmHg/mL)                 | 1.15 ± 0.58     | 3.91 ± 1.54     | 0.005            |
| EDPVR (mmHg/mL)                 | 0.95 ± 0.39     | 0.14 ± 0.04     | 0.005            |

HR, heart rate; RVEF, right ventricular ejection fraction; RVESP, right ventricular end-systolic pressure; LVESVP, left ventricular end-systolic pressure; RVEDP, right ventricular end-diastolic pressure; dP/dt max, the maximum rate of the right ventricular pressure rise; dP/dt min, the maximal rate of fall of the right ventricular pressure; PV, pressure-volume; Tau, the time constant of isovolumic relaxation; ESPVR, end-systolic pressure-volume relationship; EDPVR, end-diastolic pressure-volume relationship. P-values were calculated using the Mann-Whitney U test.

https://doi.org/10.1371/journal.pone.0247381.t001
control group (Fig 4A). Additionally, the increase in RV mass was significantly lower in the PATCH group than in the control group for both the ratio of RV mass to biventricular mass, and the ratio of RV mass to the BW of the minipigs (Fig 4A).

**Table 2. Analysis of the change in myocardial oxidative metabolism and myocardial blood flow between treatments.**

|                      | Control (n = 4) | PATCH (n = 4) | P-value |
|----------------------|----------------|--------------|---------|
| $k_{mono}$           |                |              |         |
| Rest conditions      | $-0.003 \pm 0.030$ | $-0.008 \pm 0.015$ | 0.659   |
| Stress conditions    | $-0.078 \pm 0.067$ | $0.005 \pm 0.050$ | 0.194   |
| Stress/Rest          | $-1.023 \pm 0.990$ | $0.185 \pm 0.211$ | 0.029   |
| RV efficiency        | $0.037 \pm 0.022$ | $0.311 \pm 0.213$ | 0.030   |
| **Myocardial blood flow** |                |              |         |
| Rest conditions      | $-0.235 \pm 0.331$ | $-0.128 \pm 0.221$ | 0.665   |
| Stress conditions    | $-1.565 \pm 1.569$ | $0.625 \pm 0.510$ | 0.030   |
| Stress/Rest          | $-1.323 \pm 1.979$ | $0.785 \pm 0.463$ | 0.005   |

$k_{mono}$, $^{11}$C-acetate clearance rate constant k; Stress/Rest, the ratio between the value of stress conditions and rest conditions; RV, right ventricular. The P-values were calculated using the Mann-Whitney U test.

https://doi.org/10.1371/journal.pone.0247381.t002
Fig 4. Histopathological analysis of pressure-overloaded right ventricular myocardium two months after patch implantation or sham operation. (a) Representative figures of the macropathological findings. Despite the hypertrophied RV wall, the enlargement of the RV cavity was well-controlled in the PATCH group when compared to the control group. The increase in RV mass was significantly lower in the PATCH group than in the control group for both the ratio between RV mass and biventricular mass, and the ratio between the RV mass and the BW of the
Autologous skeletal myoblast patch implantation for pressure-overloaded right heart failure

For the pathological evaluation of the liver, to identify the adverse effects of RV failure on abdominal organs, the ratio between the liver mass and BW of minipigs was significantly smaller in the PATCH group than in the control group, and the congestion around the central vein in the hepatic lobule suggested that the degree of damage by RV failure was more remarkable in the control group when compared to the PATCH group (S3 Fig).

Upregulated VEGF, HGF, and SDF-1, and downregulated NOX-2, NOX-4, ANP, BNP, TGFβ1, and CTGF in the heart after myoblast cell patch implantation

Real-time PCR was used to quantitatively assess the expression levels of myoblast cell patch-derived factors, such as vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), and stromal cell-derived factor-1 (SDF-1), as well as to assess the expression levels of myocardial hypoxia, hypertrophy, and fibrosis (Fig 5). Intramyocardial mRNA levels of VEGF, HGF, and SDF-1 were more significantly upregulated in the PATCH group than in the control group (VEGF: 1.08 ± 0.36 vs. 0.78 ± 0.06, p = 0.02; HGF: 1.34 ± 0.75 vs. 0.78 ± 0.11, p = 0.02; SDF-1: 1.26 ± 0.83 vs. 0.49 ± 0.23, p<0.01, PATCH vs. control, respectively) (Fig 5A). Intramyocardial mRNA levels of NADPH Oxidase (NOX)-2, NOX-4, atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), transforming growth factor-β1 (TGF-β1), and cellular communication network factor 2 (CCN2) were significantly downregulated in the PATCH group than in the control group (NOX-2: 0.95 ± 0.30 vs. 2.21 ± 0.84, p<0.01; NOX-4: 0.75 ±0.15 vs. 2.01 ± 0.54, p<0.01; ANP: 0.47 ± 0.26 vs. 2.40 ± 1.82, p<0.01; BNP: 0.15 ± 0.11 vs. 5.26 ± 4.61, p<0.01; TGF-β1: 0.84 ± 0.13 vs. 1.34 ± 0.21, p<0.01; CCN2: 0.39 ± 0.25 vs. 1.36 ± 1.04, p = 0.02, PATCH vs. control, respectively) (Fig 5B).

Discussion

In this study, we performed autologous skeletal myoblast patch implantation in pressure-overloaded right heart failure in a porcine model. Serial measurements of RV volume with MDCT revealed that the dilatation of the RV due to pressure overload could be attenuated by myoblast patch transplantation (Fig 2A and 2B). This was accompanied by the improvement in the systolic and diastolic functions of the RV, assessed on TTE (Fig 2C) or pressure-volume loop analysis by cardiac catheterization (Table 1), 2 months after the patch transplantation. In addition, the right ventricular myocardial oxidative metabolism and myocardial flow reserve, assessed with 

-11C-acetate PET, were significantly increased by myoblast patch transplantation.
Fig 5. Gene expression of neurohormonal factors in the heart tissue assessed using real-time PCR. (a) Intramyocardial mRNA levels of VEGF, HGF, and SDF-1 were more significantly upregulated in the PATCH group than in the control group. (b) Intramyocardial mRNA levels of NOX-2, NOX-4, ANP, BNP, TGF-β1, and CCN2 were significantly downregulated in the PATCH group as compared to the control group. The horizontal line in the middle indicates the mean, and the whiskers mark indicates the standard deviation. The P-values were calculated using the
Histological analysis showed reduced myocardial hypertrophy, reduced fibrosis, and increased aSMA and CD31 double-positive mature vessels in the myocardium, by myoblast patch transplantation (Fig 4). Gene expression profiling showed a significant upregulation of angiogenic cytokines and reduced oxidative stress markers in the myocardium by myoblast patch transplantation (Fig 5). These results suggest that, the transplantation of a myoblast patch induces angiogenesis and anti-fibrosis by means of a cytokine paracrine effect, and results in therapeutic effects in pressure-overloaded RV failure.

There have been multiple cell transplantation preclinical studies for RV dysfunction with various cell types, animal models, and administration methods [44,45]. However, so far, none of them have achieved clinical application. In the present study, we used a pressure-overloaded right heart model to target CHD patients with a systemic right ventricle, which of right ventricle is exposed to a high systemic vascular resistance for a long period. We directly attached the myoblast cells to the epicardium of the RV myocardium with heart failure, as an administration method. Our cell source has already been applied clinically for left heart failure, where its safety has been assured and the detailed mechanism has been well studied. Furthermore, our cell patch transplantation can more reliably transfer therapeutic cells to the myocardium in heart failure, compared to previously reported administration methods, such as transcoronary or intramyocardial injections. Our cell patch technology also has the advantage of not only maintaining the cell-cell connection, but also noninvasively harvesting its own extracellular matrix, deposited during culture beneath the cell patch, which allows a greater anti-heart failure effect.

Histopathologically, the loss of capillaries in the RV myocardium is a well-known feature in cases of pressure-overloaded RV dysfunction in CHD patients with systemic RV, such as hypoplastic left heart syndrome with previous Norwood/Fontan palliation [46–48]. However, the MVO$_2$ was increased by hypertrophic changes in the ventricular cardiomyocytes in a pressure-overloaded right heart [43,49–51]. Under these conditions, the RV cardiomyocytes, which were originally poorly resistant to ischemia [8,12,13], were in seriously ischemic conditions. The metabolic remodeling in cardiomyocytes owing to increased oxidative stress, due to the ischemic conditions of a pressure-overloaded RV, can cause various reactions, such as inflammation, apoptosis, and fibrosis, leading to RV dysfunction [8,12,13]. Based on these conditions of the pressure-overloaded RV myocardium, the main therapeutic mechanism in autologous skeletal myoblast patch implantation therapy—angiogenesis—may be effective for pressure-overloaded right heart failure.

The angiogenic effect of autologous skeletal myoblast patch implantation therapy has been previously proven in many of our studies on left heart failure [33,40]. The major underlying mechanism, angiogenesis, is expected to be upregulated by pro-angiogenetic cytokines from the myoblast patch, such as VEGF and HGF [34,52,53]. These cytokines act on vascular endothelial cells and vascular smooth muscle cells to promote angiogenesis along with vascular maturity of the myocardium in a pressure-overloaded right heart. Additionally, the upregulated SDF-1 expression from the patch may promote further angiogenesis, secondary to the accumulation of mesenchymal stem cells from the bone marrow on the impaired myocardium of the right ventricle [34,52–55]. In our present study, the upregulation of VEGF, HGF, and SDF-1 was observed, and the same mechanism of action is expected to work on the pressure-overloaded right ventricular myocardium. In the present study, we did not investigate the survival of the implanted myoblast cells. However, we confirmed the survival of the implanted myoblast cells for a few months.
after transplantation in our previous study on left heart failure [35,56,57], and the same survival can be expected in the right ventricle. Even after the loss of implanted myoblast cells a few months after implantation, the recruited bone marrow mesenchymal stem cell-derived vascular endothelial cells expressed angiogenic cytokines, along with the maintenance or maturation of newly developed vascular networks. Therefore, the functional recovery of heart failure is preserved even after cell loss. Moreover, as in myoblast patch treatment for left heart failure, the anti-hypertrophic effect on cardiomyocytes in the pressure-overloaded RV decreased MVO$_2$ and ameliorated myocardial dysfunction, by improving the myocardial ischemia.

In the initial stage of pressure-overloaded right heart failure, compensatory mechanisms such as volume dilatation and hypertrophic change work to maintain the RV function in a hyperdynamic state [8,12,13]. In this stage, the myocardial oxidative metabolism improves, and coronary flow reserve can be secured [43,49–51,58,59]. However, the prolonged pressure overload advances the metabolic remodeling of cardiomyocytes, owing to persistent mechanical stress on the myocardium and severe ischemic conditions [8,12,13,19,20]. Eventually, the right heart failure progresses to a decompensated stage with impaired RV function due to the reduction in cardiac reserve [13,60–62]. Considering the results of the $^{11}$C-acetate PET, the angiogenic effect of patch implantation suppresses the metabolic remodeling of cardiomyocytes and maintains the cardiac reserve of the RV, by avoiding chronic ischemic conditions. Thus, patch implantation prevents progression to a decompensated stage and maintains a hyperdynamic state of compensatory right heart failure. Additionally, from the results of cardiac function analysis, the suppressed ventricular volume dilatation and decreased end-diastolic pressure with patch implantation suggest a reduction in the RV wall stress, which can also work positively for the amelioration of right heart failure.

Conclusions

In summary, in pressure-overloaded right heart porcine models, autologous skeletal myoblast patch implantation therapy alleviated myocardial ischemia by angiogenesis and improved the myocardial oxidative metabolism as well as the myocardial blood flow. This led to the amelioration of RV diastolic and systolic functions, thereby alleviating right heart failure. This study demonstrated the potential of autologous skeletal myoblast patch implantation therapy as a novel cardiac regenerative treatment for patients with right heart failure associated with CHD.

Supporting information

**S1 Fig. Changes in the RV systolic and diastolic functions during the study.** RV systolic and diastolic functions were significantly ameliorated in the PATCH group than in the control group, at two months after patch implantation or sham operation. The red and blue numbers at each point represent the means ± standard deviation of the PATCH group and control group, respectively. P-values were calculated using the Mann-Whitney U test. $P<0.01^{**}$ versus control group. ICT, isovolumic contraction time; TAPSE, tricuspid annular plane systolic excursion; IRT, isovolumic relaxation time; RVFWT, right ventricular free wall thickness. (TIF)

**S2 Fig. Representative pressure–volume loops of the control and PATCH groups under different loading conditions.** The slope of the end-systolic pressure–volume relationship is displayed as a black straight line on top of the pressure-volume loops. The correlation of the end-diastolic pressure–volume relationship is displayed as a back straight line below the pressure-volume loops. RVP, right ventricular pressure; RV, right ventricle. (TIF)
S3 Fig. Adverse effects of RV failure on the abdominal organs. (a) Representative photomicrographs of hematoxylin-eosin staining (×40, scale bar = 300 mm; ×100, scale bar = 100 mm). Congestion around the central vein in the hepatic lobule was more marked in the control group than in the PATCH group. (b) The ratio between the liver mass and the bodyweight of minipigs was significantly lower in the PATCH group than in the control group. The horizontal line in the middle indicates the mean, and the whiskers mark indicates the standard deviation. P-values were calculated using the Mann-Whitney U test. $P<0.05^*$. (TIF)

S1 File. (XLSX)

Acknowledgments

We thank Kaori Ikuma for her expert assistance with real-time PCR and Isamu Matsuda, Ooyama Kenji, and Fumiya Oohasi for their technical support in creating the skeletal myoblast cell patches.

Author Contributions

Conceptualization: Kanta Araki, Shigeru Miyagawa, Takuji Kawamura, Yoshiki Sawa.

Data curation: Kanta Araki, Ryo Ishii, Tadashi Watabe, Akima Harada.

Formal analysis: Kanta Araki, Takuji Kawamura, Tadashi Watabe.

Funding acquisition: Kanta Araki, Shigeru Miyagawa, Yoshiki Sawa.

Investigation: Kanta Araki.

Methodology: Kanta Araki, Shigeru Miyagawa, Takuji Kawamura, Takayoshi Ueno, Yoshiki Sawa.

Project administration: Kanta Araki.

Resources: Kanta Araki.

Supervision: Shigeru Miyagawa, Takuji Kawamura, Masaki Taira, Koichi Toda, Toru Kura- tani, Takayoshi Ueno, Yoshiki Sawa.

Validation: Kanta Araki, Takuji Kawamura, Ryo Ishii, Tadashi Watabe.

Visualization: Kanta Araki, Akima Harada.

Writing – original draft: Kanta Araki.

Writing – review & editing: Shigeru Miyagawa, Takuji Kawamura, Yoshiki Sawa.

References

1. Jenkins KJ, Botto LD, Correa A, Foster E, Kupiec JK, Marino BS, et al. Public health approach to improve outcomes for congenital heart disease across the life span. J Am Heart Assoc. 2019; 8: e009450. https://doi.org/10.1161/JAHA.118.009450 PMID: 30982389

2. Spector LG, Menk JS, Knight JH, McCracken C, Thomas AS, Vinocur JM, et al. Trends in long-term mortality after congenital heart surgery. J Am Coll Cardiol. 2018; 71: 2434–2446. https://doi.org/10.1016/j.jacc.2018.03.491 PMID: 29793633

3. Jenkins KJ, Honein MA. Public health approach to decrease mortality for congenital heart defects: dying too soon. J Am Coll Cardiol. 2018; 71: 2447–2449. https://doi.org/10.1016/j.jacc.2018.03.489 PMID: 29793634
4. Stout KK, Broberg CS, Book WM, Cecchin F, Chen JM, Dimopoulos K, et al. Chronic heart failure in congenital heart disease: A scientific statement from the American Heart Association. Circulation. 2016; 133: 770–801. https://doi.org/10.1161/CIR.0000000000000352 PMID: 26787728

5. Fahed AC, Roberts AE, Mital S, Lakdawala NK. Heart failure in congenital heart disease: a confluence of acquired and congenital. Heart Fail Clin. 2014; 10:219–227. https://doi.org/10.1016/j.hfc.2013.09.017 PMID: 24275306

6. Saha P, Potiny P, Rigdon J, Morello M, Tcheandjieu C, Romfh A, et al. Substantial cardiovascular morbidity in adults with lower-complexity congenital heart disease. Circulation. 2019; 139: 1889–1899. https://doi.org/10.1161/CIRCULATIONAHA.118.037064 PMID: 30813762

7. Williams RG, Pearson GD, Barst RJ, Child JS, del Nido P, Gersony WM, et al. Report of the National Heart, Lung, and Blood Institute Working Group on research in adult congenital heart disease. J Am Coll Cardiol. 2006; 47: 701–707. https://doi.org/10.1016/j.jacc.2005.08.074 PMID: 16487831

8. Reddy S, Bernstein D. The vulnerable right ventricle. Curr Opin Pediatr. 2015; 27: 563–568. https://doi.org/10.1097/MOP.0000000000000268 PMID: 26262580

9. Geva T, Mulder B, Gauvreau K, Babu-Narayan SV, Wald RM, Hickey K, et al. Preoperative predictors of death and sustained ventricular tachycardia after pulmonary valve replacement in patients with repaired tetralogy of fallot enrolled in the INDICATOR Cohort. Circulation. 2018; 138: 2106–2115. https://doi.org/10.1161/CIRCULATIONAHA.118.034740 PMID: 30030416

10. Gellat M, Hamilton RM, McCrindle BW, Connelly M, Davis A, Harris L, et al. Arrhythmia and mortality after the Mustard procedure: a 30-year single-center experience. J Am Coll Cardiol. 1997; 29: 194–201. https://doi.org/10.1016/s0735-1097(96)00424-x PMID: 8996314

11. Rutledge JM, Nihill MR, Fraser CD, Smith OE, McMahon CJ, Bezold LJ. Outcome of 121 patients with congenitally corrected transposition of the great arteries. Pediatr Cardiol. 2002; 23: 137–145. https://doi.org/10.1007/s00246-001-0037-8 PMID: 11889523

12. Haller C, Friedberg MK, Laflamme MA. The role of regenerative therapy in the treatment of right ventricular failure: a literature review. Stem Cell Res Ther. 2020; 11: 502. https://doi.org/10.1186/s13287-020-02022-w PMID: 33239066

13. Reddy S, Bernstein D. Molecular mechanisms of right ventricular failure. Circulation. 2015; 132: 1734–1742. https://doi.org/10.1161/CIRCULATIONAHA.114.012975 PMID: 26527692

14. Khairy P, Clair M, Fernandes SM, Blume ED, Powell AJ, Newburger JW, et al. Cardiovascular outcomes after the arterial switch operation for D-transposition of the great arteries. Circulation. 2013; 127: 331–339. https://doi.org/10.1161/CIRCULATIONAHA.112.135046 PMID: 23239839

15. Ou P, Khraiche D, Celermajer DS, Agnoletti G, Le Quan Sang KH, Thalabard JC, et al. Mechanisms of coronary complications after the arterial switch for transposition of the great arteries. J Thorac Cardiovasc Surg. 2013; 145: 1263–1269. https://doi.org/10.1016/j.jtcvs.2012.06.009 PMID: 22795438

16. Hauser M, Bengel FM, Kühn A, Sauer U, Nekolla SG, Eicken A, et al. Myocardial perfusion and coronary flow reserve assessed by positron emission tomography in patients after Fontan-like operations. Pediatr Cardiol. 2003; 24: 386–392. https://doi.org/10.1007/s00246-002-0355-5 PMID: 12545320

17. Hauser M, Bengel FM, Hager A, Kuehn A, Nekolla SG, Kaemmerer H, et al. Impaired myocardial blood flow and coronary flow reserve of the anatomical right systemic ventricle in patients with congenitally corrected transposition of the great arteries. Heart. 2003; 89: 1231–1235. https://doi.org/10.1136/heart.89.10.1231 PMID: 12975428

18. Hauser M, Kuehn A, Hess J. Myocardial perfusion in patients with transplantation of the great arteries after arterial switch operation. Circulation. 2003; 107: e126; author reply e126. https://doi.org/10.1161/01.CIR.0000071211.20538.25 PMID: 12742975

19. Noly PE, Haddad F, Ataam JA, Langer N, Dorfmüller P, Loisel F, et al. The importance of capillary density-stroke work mismatch for right ventricular adaptation to chronic pressure overload. J Thorac Cardiovasc Surg. 2017; 154: 2070–2079. https://doi.org/10.1016/j.jtcvs.2017.05.102 PMID: 28712579

20. Gómez A, Bialostozky D, Zajarias A, Santos E, Palomar A, Martinez ML, et al. Right ventricular ischemia in patients with primary pulmonary hypertension. J Am Coll Cardiol. 2001; 38: 1137–1142. https://doi.org/10.1016/s0735-1097(01)01496-6 PMID: 11583894

21. van der Bom T, Winter MM, Bouma BJ, Groenink M, Vliegen HW, Pieper PG, et al. Effect of valsartan on systemic right ventricular function: a double-blind, randomized, placebo-controlled pilot trial. Circulation. 2013; 127: 322–330. https://doi.org/10.1161/CIRCULATIONAHA.112.135392 PMID: 23247302

22. Hsu DT, Zak V, Mahony L, Sleeper LA, Atz AM, Levine JC, et al. Enalapril in infants with single ventricle: results of a multicenter randomized trial. Pediatric Heart Network Investigators. Circulation. 2010; 122: 333–340. https://doi.org/10.1161/CIRCULATIONAHA.109.927988 PMID: 20625111
23. Winter MM, Bouma BJ, Groenink M, Konings TC, Tijssen JG, van Veldhuisen DJ, et al. Latest insights in therapeutic options for systemic right ventricular failure: a comparison with left ventricular failure. Heart. 2009; 95:960–963. https://doi.org/10.1136/hrt.2008.156265 PMID: 19033293

24. Babu-Narayan SV, Uebing A, Davlouros PA, Kemp M, Davidson S, Dimopoulos K, et al. Randomised trial of ramipril in repaired tetralogy of Fallot and pulmonary regurgitation: the APPROPRIATE study (Ace inhibitors for Potential PRevention Of the deleterious effects of Pulmonary Regurgitation In Adults with repaired TETralogy of Fallot). Int J Cardiol. 2012; 154: 299–305. https://doi.org/10.1016/j.ijcard.2010.09.057 PMID: 20970202

25. Miller JR, Eghtesady P. Ventricular assist device use in congenital heart disease with a comparison to heart transplant. J Comp Eff Res. 2014; 3: 533–546. https://doi.org/10.102217/cer.14.42 PMID: 25390804

26. Davies RR, Russo MJ, Yang J, Quaegebeur JM, Mosca RS, Chen JM. Listing and transplanting adults with congenital heart disease. Circulation. 2011; 123: 759–767. https://doi.org/10.1161/CIRCULATIONAHA.110.960260 PMID: 21300954

27. Weinstein S, Bello R, Pizarro C, Fynn-Thompson F, Kirklin J, Guleserian K, et al. The use of the Berlin Heart EXCOR in patients with functional single ventricle. J Thorac Cardiovasc Surg. 2014; 147: 697–704. https://doi.org/10.1016/j.jtcvs.2013.10.030 PMID: 24290716

28. Dipchand AI, Kirk R, Edwards LB, Kucheryavaya AY, Benden C, Christie JD, et al. The Registry of the International Society for Heart and Lung Transplantation: Sixteenth Official Pediatric Heart Transplantation Report—2013: focus theme: age. J Heart Lung Transplant. 2013; 32: 979–988. https://doi.org/10.1016/j.healun.2013.08.005 PMID: 24054808

29. Chen JM, Davies RR, Mitral SR, Mercando ML, Addonizio LJ, Pinney SP, et al. Trends and outcomes in transplantation for complex congenital heart disease: 1984 to 2004. Ann Thorac Surg. 2004; 78: 1352–1361. https://doi.org/10.1016/j.athoracsur.2004.09.057 PMID: 15464499

30. Bartunek J, Terzic A, Behfar A, Wijns W. Clinical experience with regenerative therapy in heart failure: Advancing care with cardiopoietic stem cell interventions. Circ Res. 2018; 122: 1344–1346. https://doi.org/10.1161/CIRCRESAHA.118.312753 PMID: 29748365

31. Stefanelli G, Pirro F,オリオロ, Giovanardi P, Mell M, Concari M, et al. Cell therapy and left ventricular restoration for ischemic cardiomyopathy: long-term results of a perspective, randomized study. Minerva Cardioangiol. 2018; 67: 64–72. https://doi.org/10.23736/S0026-4725.18.04800-4 PMID: 30390145

32. Kondoh H, Sawa Y, Miyagawa S, Kitagawa SS, Memon IA, Kawaguchi N, et al. Longer preservation of cardiac performance by sheet-shaped myoblast implantation in dilated cardiomyopathic hamsters. Cardiovasc Res. 2006; 69: 466–475. https://doi.org/10.1016/j.cardiores.2005.11.005 PMID: 16423569

33. Hamdi H, Furuta A, Bellamy V, Bel A, Puymirat E, Peyrard S, et al. Cell delivery: intramyocardial injections or epicardial deposition? A head-to-head comparison. Ann Thorac Surg. 2009; 87: 1196–1203. https://doi.org/10.1016/j.athoracsur.2008.12.074 PMID: 19324150

34. Memon IA, Sawa Y, Fukushima N, Matsumiya G, Miyagawa S, Tabetani S, et al. Repair of impaired myocardium by means of implantation of engineered autologous myoblast sheets. J Thorac Cardiovasc Surg. 2005; 130: 1333–1341. https://doi.org/10.1016/j.jtcvs.2005.07.023 PMID: 16256786

35. Hata H, Matsumiya G, Miyagawa S, Kondoh H, Kawaguchi N, Matsuura N, et al. Grafted skeletal myoblast sheets attenuate myocardial remodeling in pacing-induced canine heart failure model. J Thorac Cardiovasc Surg. 2007; 133: 918–924. https://doi.org/10.1016/j.jtcvs.2006.01.024 PMID: 17000305

36. Shirasaka T, Miyagawa S, Fukushima S, Kawaguchi N, Nakatani S, Daimon T, et al. Skeletal myoblast cell sheet implantation ameliorates both systolic and diastolic cardiac performance in canine dilated cardiomyopathy model. Transplantation. 2016; 100: 295–302. https://doi.org/10.1097/TP.0000000000001014 PMID: 26636739

37. Hoashi T, Matsumiya G, Miyagawa S, Ichikawa H, Ueno T, Ono M, et al. Skeletal myoblast sheet transplantation improves the diastolic function of a pressure-overloaded right heart. J Thorac Cardiovasc Surg. 2009; 138: 460–467. https://doi.org/10.1016/j.jtcvs.2009.02.018 PMID: 19619796

38. Miyagawa S, Domae K, Yoshikawa Y, Fukushima S, Nakamura T, Saito A, et al. Phase I clinical trial of autologous stem cell-sheet transplantation therapy for treating cardiomyopathy. J Am Heart Assoc. 2017; 6: e003918. https://doi.org/10.1161/JAHA.116.003918 PMID: 28381469

39. Sawa Y, Yoshikawa Y, Toda K, Fukushima S, Yamazaki K, Ono M, et al. Safety and efficacy of autologous skeletal myoblast sheets (TCD-51073) for the treatment of severe chronic heart failure due to ischemic heart disease. Circ J. 2015; 79: 991–999. https://doi.org/10.1253/circj.CJ-15-0243 PMID: 25912561

40. Yoshikawa Y, Miyagawa S, Toda K, Saito A, Sakata Y, Sawa Y. Myocardial regenerative therapy using a scaffold-free skeletal-muscle-derived cell sheet in patients with dilated cardiomyopathy even under a left ventricular assist device: a safety and feasibility study. Surg Today. 2018; 48: 200–210. https://doi.org/10.1007/s00595-017-1571-1 PMID: 28821963
41. Araki K, Taira M, Miyagawa S, Kanaya T, Okuda N, Toda K, et al. Autologous skeletal myoblast sheet implantation for pediatric dilated cardiomyopathy: A case report. Gen Thorac Cardiovasc Surg. 2020. https://doi.org/10.1007/s11748-020-01540-x PMID: 3319619

42. Croteau E, Gascon S, Bentourkia M, Langlois R, Rousseau JA, Lecomte R, et al. [11C]Acetate rest-protocol to assess myocardial perfusion and oxygen consumption reserve in a model of congestive heart failure in rats. Nucl Med Biol. 2012; 39: 287–294. https://doi.org/10.1016/j.nuclmedbio.2011.07.010 PMID: 22079038

43. Yoshinaga K, Ohira H, Tsujino I, Manabe NO, Mielniczuk L, Beanlands RSSB, et al. Attenuated right ventricular energetics evaluated using 11C-acetate PET in patients with pulmonary hypertension. Eur J Nucl Med Mol Imaging. 2014; 41: 1240–1250. https://doi.org/10.1007/s00259-014-2736-4 PMID: 24615469

44. Loisel F, Provost B, Haddad F, Guilhaire J, Amsallem M, Vrtovec B, et al. Stem cell therapy targeting the right ventricle in pulmonary arterial hypertension: is it a potential avenue of therapy? Pulm Circ. 2018; 8: 2045893218755979. https://doi.org/10.1177/2045893218755979 PMID: 29480154

45. Lambert V, Goudon E, Capderou A, Le Bret E, Ly M, Dinanian S, et al. Right ventricular failure secondary to chronic overload in congenital heart diseases: benefits of cell therapy using human embryonic stem cell-derived cardiac progenitors. J Thorac Cardiovasc Surg. 2015; 149: 706–715.e1. https://doi.org/10.1016/j.jtcvs.2014.11.033 PMID: 25583108

46. Chery J, Wong J, Huang S, Wang S, Si MS. Morphometry of coronary capillaries in hypoplastic left heart syndrome. Tissue Eng Part B Rev. 2016; 22: 459–469. https://doi.org/10.1089/ten.TEB.2016.0136 PMID: 27245633

47. Padalino MA, Castellani C, Toffoli S, Delta Barbera M, Milanesi O, Thiene G, et al. Pathological changes and myocardial remodelling related to the mode of shunting following surgical palliation for hypoplastic left heart syndrome. Cardiol Young. 2008; 18: 415–422. https://doi.org/10.1017/S1047951108002461 PMID: 18588727

48. Salih C, Sheppard MN, Ho SY. Morphometry of coronary capillaries in hypoplastic left heart syndrome. Ann Thorac Surg. 2004; 77: 903–907. https://doi.org/10.1016/j.athoracsur.2003.07.046 PMID: 14992895

49. Wong YY, Westerhof N, Ruiter G, Lubberink M, Rajmakers P, Knaapen P, et al. Systolic pulmonary artery pressure and heart rate are main determinants of oxygen consumption in the right ventricular myocardium of patients with idiopathic pulmonary arterial hypertension. Eur J Heart Fail. 2011; 13: 1290–1295. https://doi.org/10.1093/eurjhf/hfr140 PMID: 22016028

50. Yoshinaga K, Ohira H, Tsujino I, Manabe O, Sato T, Kato C, et al. Right Ventricular Metabolism and Its Efficiency. In: Kuge Y, Shiga T, Tamaki N, editors. Perspectives on Nuclear Medicine for Molecular Diagnosis and Integrated Therapy. Springer, Tokyo; 2001. pp 193–207. https://doi.org/10.1007/978-4-311-59959-7_59 PMID: 11962381

51. Wong YY, Ruiter G, Lubberink M, Rajmakers PG, Knaapen P, Marcus JT, et al. Right ventricular failure in idiopathic pulmonary arterial hypertension is associated with inefficient myocardial oxygen utilization. Circ Heart Fail. 2011; 4: 700–706. https://doi.org/10.1161/CIRCHEARTFAILURE.111.962381 PMID: 21900188

52. Iseoka H, Miyagawa S, Saito A, Harada A, Sawaya R. Role and therapeutic effects of skeletal muscle-derived non-myogenic cells in a rat myocardial infarction model. Stem Cell Res Ther. 2020; 11: 69. https://doi.org/10.1186/s13287-020-1582-5 PMID: 32070429

53. Sekiya N, Matsumiya G, Miyagawa S, Saito A, Shimizu T, Okano T, et al. Layered implantation of myoblast sheets attenuates adverse cardiac remodeling of the infarcted heart. J Thorac Cardiovasc Surg. 2009; 138: 985–993. https://doi.org/10.1016/j.jtcs.2009.02.004 PMID: 19769884

54. Ziff OJ, Bromage DI, Yellon DM, Davidson SM. Therapeutic strategies utilizing SDF-1α in ischaemic cardiomyopathy. Cardiovasc Res. 2018; 114: 358–367. https://doi.org/10.1093/cvr/cvx203 PMID: 29040243

55. Penn MS, Pastore J, Miller T, Aras R. SDF-1 in myocardial repair. Gene Ther. 2012; 19: 583–587. https://doi.org/10.1038/gt.2012.32 PMID: 22673496

56. Kainuma S, Miyagawa S, Fukushima S, Pearson J, Chen YC, Saito A, et al. Cell-sheet therapy with omentopexy promotes arteriogenesis and improves coronary circulation physiology in a failing heart. Mol Ther. 2015; 23: 374–386. https://doi.org/10.1038/mt.2014.225 PMID: 25421595

57. Sawa Y, Miyagawa S. Present and future perspectives on cell sheet-based myocardial regeneration therapy. Biomed Res Int. 2013; 2013: 583912. https://doi.org/10.1155/2013/583912 PMID: 24369013

58. Frump AL, Bonnet S, de Jesus Perez VA, Lahm T. Emerging role of angiogenesis in adaptive and maladaptive right ventricular remodeling in pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2018; 314: L443–L460. https://doi.org/10.1152/ajplung.00374.2017 PMID: 29097426

59. Ryan JJ, Archer SL. The right ventricle in pulmonary arterial hypertension: disorders of metabolism, angiogenesis and adrenergic signaling in right ventricular failure. Circ Res. 2014; 115: 176–188. https://doi.org/10.1161/CIRCRESAHA.113.301129 PMID: 24951766
60. Ren X, Johns RA, Gao WD. Right heart in pulmonary hypertension: from adaptation to failure. Pulm Circ. 2019; 9: 2045894019845611. https://doi.org/10.1177/2045894019845611 PMID: 30942134

61. van der Bruggen CEE, Tedford RJ, Handoko ML, van der Velden J, de Man FS. RV pressure overload: from hypertrophy to failure. Cardiovasc Res. 2017; 113: 1423–1432. https://doi.org/10.1093/cvr/cvx145 PMID: 28957530

62. Guimaron S, Guillaume J, Amsallem M, Haddad F, Fadel E, Mercie O. Current knowledge and recent advances of right ventricular molecular biology and metabolism from congenital heart disease to chronic pulmonary hypertension. Biomed Res Int. 2018; 2018: 1981568. https://doi.org/10.1155/2018/1981568 PMID: 29581963